Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 789,300 shares, a decline of 19.9% from the March 15th total of 985,700 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is […]
StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) from a hold rating to a sell rating in a report published on Monday morning. A number of other research analysts also recently weighed in on ORMP. Canaccord Genuity Group downgraded Oramed Pharmaceuticals from a buy rating to a hold rating and dropped their price […]
Private Portfolio Partners LLC lowered its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) by 20.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 53,600 shares of the biotechnology company’s stock after selling 13,800 shares during the period. Private Portfolio Partners LLC’s holdings in Oramed Pharmaceuticals were worth $645,000 at the end […]
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald cut Oramed Pharmaceuticals from an “overweight” rating to […]
/PRNewswire/ Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis.